India’s Dr Reddy’s Laboratories (NYSE: RDY) has received a fresh Form 483 from the US Food and Drug Administration, keeping regulatory scrutiny fixed on one of its biologics manufacturing sites just ...
India’s pharmaceutical industry is witnessing a surge in global partnerships, with countries such as Switzerland, Uzbekistan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results